Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

  1. Home
  3. Research Domains
  5. Biomedical And Clinical Sciences
  7. Oncology And Carcinogenesis
  9. Predictive And Prognostic Markers
  11. Risk Classification Of Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin

Risk Classification of Patients With Advanced Urothelial Carcinoma Treated With Enfortumab Vedotin

Gaku Ishikawa1, Yuto Matsushita1, Yuichi Kitagawa2

  • 1Department of Urology, Hamamatsu University School of Medicine, Hamamatsu, Japan.

Cancer Diagnosis & Prognosis
|November 6, 2024

Related Experiment Videos

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
09:28

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Published on: May 12, 2019

10.1K
Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma
06:39

Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

Published on: November 22, 2019

7.7K
Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.6K

View abstract on PubMed

Summary
This summary is machine-generated.

High C-reactive protein and hypercalcemia predict outcomes for advanced urothelial carcinoma patients treated with enfortumab vedotin (EV). A new risk model using these factors improves outcome prediction for this cancer treatment.

Area of Science:

  • Oncology
  • Medical Science

Background:

  • Enfortumab vedotin (EV) is a key treatment for advanced urothelial carcinoma (UC) post-platinum chemotherapy and immunotherapy.
  • Limited data exists on prognostic factors and risk stratification for patients receiving EV.
  • Identifying predictive factors is crucial for optimizing treatment strategies.

Purpose of the Study:

  • To identify clinical prognostic factors for advanced UC patients treated with EV.
  • To develop and validate a novel risk classification model based on these factors.

Main Methods:

  • A multicenter retrospective study of advanced UC patients treated with EV.
  • Assessment of progression-free survival (PFS) and overall survival (OS).
  • Investigation of prognostic factors and validation of a risk classification model.
Keywords:
Enfortumab Vedotinprognostic factorrisk classification

Related Experiment Videos

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis
09:28

Patient-derived Orthotopic Xenograft Models for Human Urothelial Cell Carcinoma and Colorectal Cancer Tumor Growth and Spontaneous Metastasis

Published on: May 12, 2019

10.1K
Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma
06:39

Technical Modification of the Terminal Ureter During Total Transperitoneal Laparoscopic Nephroureterectomy for Upper Urinary Tract Urothelial Carcinoma

Published on: November 22, 2019

7.7K
Culture of Bladder Cancer Organoids as Precision Medicine Tools
08:39

Culture of Bladder Cancer Organoids as Precision Medicine Tools

Published on: December 28, 2021

4.6K

Main Results:

  • Median PFS was 7.1 months and median OS was 16.3 months.
  • Elevated C-reactive protein (CRP ≥0.5 mg/dl) and hypercalcemia (>10.2 mg/dl) were significant negative prognostic factors for both PFS and OS.
  • A three-group risk classification model demonstrated significant differences in PFS and OS (c-indices: PFS 0.766, OS 0.800).

Conclusions:

  • The developed risk classification model incorporating CRP and hypercalcemia effectively predicts outcomes in advanced UC patients treated with EV.
  • This model aids in stratifying patients and anticipating treatment response.